Identification of the mutations enabled the creation of transgenic animal models expressing abnormal APP and/or or presenilin (van Tijn et al., 2011; Sabbagh et al., 2013), featuring AD-like pathology, and allowing the use of invasive methods and observations of disease progression from the earliest stages. The gene discussed is APP; the disease is Alzheimer disease.